

Histone deacetylase (HDAC) Inhibitors - Competitive Landscape, Market and Pipeline Analysis, 2017

https://marketpublishers.com/r/HE6FB2A2F17EN.html

Date: November 2017 Pages: 0 Price: US\$ 3,250.00 (Single User License) ID: HE6FB2A2F17EN

Abstracts

This report can be delivered to the clients within 25 Hours

DelveInsight's, "Histone deacetylase (HDAC) Inhibitors - Competitive Landscape, Market, and Pipeline Analysis, 2017" report provides comprehensive insights of the ongoing therapeutic research and development across mechanism of action. The report provides information on all the pipeline drugs and comparative analysis at various stages covering all clinical, pre-clinical as well as discovery products. Furthermore, the report also contains detailed information of marketed products along with historical and forecasted sales.

The report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by the DelveInsight team of industry experts.Secondary sources information and data has been collected from various printable and non-printable sources like search engines, News websites, Government Websites, Trade Journals, White papers, Magazines, Trade associations, Books, Industry Portals, Industry Associations and access to available databases.

The report comprehensively includes:

In-depth analysis of the 28+ pipeline assets and 5 marketed products

Therapeutic assessment by molecule type, route of administration, monotherapy and combination products

Licensing, Deals and Patent details (marketed and pipeline) related to HDAC inhibitors are also covered



Insights on marketed products including detailed marketed product profiles. Also, includes Historical and Forecasted sales for Marketed products

Information on various technologies involved in the development of pipeline therapeutics along with drug designations is also provided



Contents

- **Executive Summary**
- Overview
- Competitive Landscape
- Collaboration
- Technology
- Designation
- Active Pipeline coverage by Indication
- Marketed and Pipeline Drugs
- Marketed Drug Profiles
- Farydak: Novartis
- **Product Description**
- Regulatory Milestones
- Research and Development
- Other Clinical Activities
- **Product Development Activities**
- Farydak Global Sales
- Farydak Analyst Insights
- Beleodaq: Spectrum Pharmaceuticals
- **Product Description**
- Regulatory Milestones
- Research and Development
- Other Clinical Activities
- **Product Development Activities**
- **Beleodaq Global Sales**
- **Beleodaq Analyst Insights**
- Epidaza: Chipscreen Bioscience
- **Product Description**
- Regulatory Milestones
- Research and Development
- Other Clinical Activities
- **Product Development Activities**
- Epidaza Analyst Insights
- Zolinza: Merck
- Product Description
- **Regulatory Milestones**
- Research and Development
- Other Clinical Activities




- Product Development Activities
- Zolinza Global Sales
- Zolinza Analyst Insights
- Istodax: Gloucester Pharmaceuticals
- **Product Description**
- Regulatory Milestones
- Research and Development
- **Other Clinical Activities**
- Product Development Activities
- Istodax Global Sales
- Istodax Analyst Insights
- Market Positioning of HDAC Inhibitors
- HDAC Inhibitors Market Evaluation
- HDAC Inhibitors Class Share Evaluation
- **Pipeline Therapeutics**
- **Comparative Analysis**
- Late Stage Products (Phase III)
- Comparative Analysis
- Entinostat: Syndax Pharmaceuticals
- Product Description
- Research and Development
- Product Development Activities
- Pracinostat: MEI Pharma
- Product Description
- **Research and Development**
- Product Development Activities
- Givinostat: Italfarmaco
- **Product Description**
- Research and Development
- **Product Development Activities**
- Mid-Stage Products (Phase II)
- Comparative Analysis
- Mocetinostat: Mirati Therapeutic
- **Product Description**
- **Research and Development**
- **Product Development Activities**
- Quisinostat: Janssen
- Product Description
- Research and Development





Product Development Activities VRx-3996: Viracta Therapeutics **Product Description Research and Development Product Development Activities** Sulforadex: Evgen Pharma **Product Description** Research and Development **Product Development Activities** CHR 5154: Chroma Therapeutics **Product Description Research and Development Product Development Activities** CUDC 907: Curis **Product Description** Research and Development **Product Development Activities Ricolinostat: Celgene Corporation Product Description** Research and Development **Product Development Activities** Remetinostat: TetraLogic Pharmaceuticals **Product Description** Research and Development **Product Development Activities** Abexinostat: Celera Genomics Group **Product Description** Research and Development **Product Development Activities Resminostat: 4SC Product Description** Research and Development **Product Development Activities** FRM 0334: FORUM Pharmaceuticals **Product Description Research and Development Product Development Activities** Early Stage Products (Phase I) **Comparative Analysis** Histone deacetylase (HDAC) Inhibitors - Competitive Landscape, Market and Pipeline Analysis, 2017





- Citarinostat: Celgene Corporation
- Product Description
- Research and Development
- Product Development Activities
- AR-42: Arno Therapeutics
- Product Description
- Research and Development
- **Product Development Activities**
- EDO S101: Mundipharma International
- **Product Description**
- Research and Development
- **Product Development Activities**
- **Pre-clinical Products**
- Comparative Analysis
- PCI-34051: Pharmacyclics
- **Product Description**
- Research and Development
- **Product Development Activities**
- HG 3001: HitGen
- Product Description
- Research and Development
- **Product Development Activities**
- CG-1255: CircaGen Pharmaceutical
- Product Description
- Research and Development
- Product Development Activities
- CG-1521: CircaGen Pharmaceutical
- **Product Description**
- Research and Development
- **Product Development Activities**
- Trichostatin A: Errant Gene Therapeutics
- **Product Description**
- Research and Development
- **Product Development Activities**
- QTX-125: Quimatryx
- Product Description
- Research and Development
- **Product Development Activities**
- QTX-153: Quimatryx



Product Description Research and Development Product Development Activities ACY 1083: Regenacy Pharmaceuticals Product Description Research and Development **Product Development Activities** ACY-738: Celgene Corporation Product Description **Research and Development Product Development Activities Therapeutic Assessment** Assessment by Monotherapy Products Assessment by Route of Administration Assessment by Stage and Route of Administration Assessment by Molecule Type Assessment by Stage and Molecule Type Institutional Products Inactive Products **Comparative Analysis**

Market Drivers and Barriers

Appendix



List Of Tables

LIST OF TABLES

- Table 1: Active Pipeline Coverage by Indication
- Table 2: Marketed and Pipeline HDAC Inhibitors
- Table 3: Total Products for HDAC Inhibitors
- Table 4: Late Stage Products (Phase III)
- Table 5: Mid Stage Products (Phase II)
- Table 6: Pre-clinical Products
- Table 7: Assessment by Monotherapy Products
- Table 8: Assessment by Route of Administration
- Table 9: Assessment by Stage and Route of Administration
- Table 10: Assessment by Molecule Type
- Table 11: Assessment by Stage and Molecule Type
- Table 12: Dormant Products
- Table 13: Discontinued Products





List Of Figures

LIST OF FIGURES

- Figure 1: Structure of HDAC Inhibitors
- Figure 2: Mechanism of HDAC Inhibitors
- Figure 3: Marketed and Pipeline HDAC Inhibitors
- Figure 4: Farydak Historical and Forecasted Global Sales (2015-2023)
- Figure 5: Market Evolution (2015-2023)
- Figure 6: Total Active Products for HDAC Inhibitors
- Figure 7: Total Products for HDAC Inhibitors
- Figure 8: Late Stage Products (Phase III)
- Figure 9: Entinostat Forecasted Sales (2019-2023)
- Figure 10: Mid Stage Products (Phase II)
- Figure 11: Early Stage Products (Phase I)
- Figure 12: Pre-clinical Products
- Figure 13: Assessment by Monotherapy Products
- Figure 14: Assessment by Route of Administration
- Figure 15: Assessment by Stage and Route of Administration
- Figure 16: Assessment by Molecule Type
- Figure 17: Assessment by Stage and Molecule Type
- Figure 18: Inactive Products



I would like to order

Product name: Histone deacetylase (HDAC) Inhibitors - Competitive Landscape, Market and Pipeline Analysis, 2017

Product link: https://marketpublishers.com/r/HE6FB2A2F17EN.html

Price: US\$ 3,250.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service: info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <u>https://marketpublishers.com/r/HE6FB2A2F17EN.html</u>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name: Last name: Email: Company: Address: City: Zip code: Country: Tel: Fax: Your message:

**All fields are required

Custumer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <u>https://marketpublishers.com/docs/terms.html</u>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970



Histone deacetylase (HDAC) Inhibitors - Competitive Landscape, Market and Pipeline Analysis, 2017